{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Three point mutations in αSyn are associated with early-onset familial PD: A30P, E46K, and A53T. Recent data suggests cellular toxicity is caused by a soluble oligomeric species, a precursor to amyloid forms of αSyn.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links αSyn mutations to PD and identifies soluble oligomers as a causative mechanism for neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The 20S proteasome and liposomes were used to assess αSyn fragmentation, conformation, and association reactions. The rate of soluble oligomer formation correlated with disease-associated mutations.",
          "judgment": "Yes",
          "reasoning": "The assay models proteasome-mediated αSyn truncation and liposome interaction, both relevant to PD pathogenesis. The focus on soluble oligomers aligns with the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wildtype αSyn and mutant variants (A30P, E46K, A53T) were tested. The wildtype protein was cleaved and formed oligomers at a slower rate.",
              "judgment": "Yes",
              "reasoning": "Wildtype αSyn served as a control for mutant variants. Replicates are implied by the comparative analysis of multiple variants.",
              "next_step_or_outcome": "Proceed to Sub-step 3c"
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "No explicit mention of other pathogenic/benign variants being used as controls beyond wildtype and the three mutations.",
              "judgment": "No",
              "reasoning": "The study does not describe additional pathogenic/benign variants as controls for statistical comparison.",
              "next_step_or_outcome": "Max PS3_supporting/BS3_supporting"
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "No statistical tests or OddsPath calculations are explicitly reported.",
              "judgment": "No",
              "reasoning": "The abstract lacks statistical validation or quantitative measures of pathogenicity.",
              "next_step_or_outcome": "Proceed to Sub-step 4b"
            },
            {
              "step_name": "Sub-step 4b: No OddsPath Calculation",
              "extracted_paper_info": "Three pathogenic variants (A30P, E46K, A53T) were compared to wildtype. No additional control variants are described.",
              "judgment": "10 or less",
              "reasoning": "Only three pathogenic variants are analyzed, totaling fewer than 10 controls.",
              "next_step_or_outcome": "Max PS3_supporting"
            }
          ]
        }
      ],
      "evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Three point mutations in αSyn are associated with early-onset familial PD: A30P, E46K, and A53T. Recent data suggests cellular toxicity is caused by a soluble oligomeric species, a precursor to amyloid forms of αSyn.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links αSyn mutations to PD and identifies soluble oligomers as a causative mechanism for neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The 20S proteasome and liposomes were used to assess αSyn fragmentation, conformation, and association reactions. The rate of soluble oligomer formation correlated with disease-associated mutations.",
          "judgment": "Yes",
          "reasoning": "The assay models proteasome-mediated αSyn truncation and liposome interaction, both relevant to PD pathogenesis. The focus on soluble oligomers aligns with the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wildtype αSyn and mutant variants (A30P, E46K, A53T) were tested. The wildtype protein was cleaved and formed oligomers at a slower rate.",
              "judgment": "Yes",
              "reasoning": "Wildtype αSyn served as a control for mutant variants. Replicates are implied by the comparative analysis of multiple variants.",
              "next_step_or_outcome": "Proceed to Sub-step 3c"
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "No explicit mention of other pathogenic/benign variants being used as controls beyond wildtype and the three mutations.",
              "judgment": "No",
              "reasoning": "The study does not describe additional pathogenic/benign variants as controls for statistical comparison.",
              "next_step_or_outcome": "Max PS3_supporting/BS3_supporting"
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "No statistical tests or OddsPath calculations are explicitly reported.",
              "judgment": "No",
              "reasoning": "The abstract lacks statistical validation or quantitative measures of pathogenicity.",
              "next_step_or_outcome": "Proceed to Sub-step 4b"
            },
            {
              "step_name": "Sub-step 4b: No OddsPath Calculation",
              "extracted_paper_info": "Three pathogenic variants (A30P, E46K, A53T) were compared to wildtype. No additional control variants are described.",
              "judgment": "10 or less",
              "reasoning": "Only three pathogenic variants are analyzed, totaling fewer than 10 controls.",
              "next_step_or_outcome": "Max PS3_supporting"
            }
          ]
        }
      ],
      "evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Three point mutations in αSyn are associated with early-onset familial PD: A30P, E46K, and A53T. Recent data suggests cellular toxicity is caused by a soluble oligomeric species, a precursor to amyloid forms of αSyn.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links αSyn mutations to PD and identifies soluble oligomers as a causative mechanism for neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The 20S proteasome and liposomes were used to assess αSyn fragmentation, conformation, and association reactions. The rate of soluble oligomer formation correlated with disease-associated mutations.",
          "judgment": "Yes",
          "reasoning": "The assay models proteasome-mediated αSyn truncation and liposome interaction, both relevant to PD pathogenesis. The focus on soluble oligomers aligns with the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wildtype αSyn and mutant variants (A30P, E46K, A53T) were tested. The wildtype protein was cleaved and formed oligomers at a slower rate.",
              "judgment": "Yes",
              "reasoning": "Wildtype αSyn served as a control for mutant variants. Replicates are implied by the comparative analysis of multiple variants.",
              "next_step_or_outcome": "Proceed to Sub-step 3c"
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "No explicit mention of other pathogenic/benign variants being used as controls beyond wildtype and the three mutations.",
              "judgment": "No",
              "reasoning": "The study does not describe additional pathogenic/benign variants as controls for statistical comparison.",
              "next_step_or_outcome": "Max PS3_supporting/BS3_supporting"
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "No statistical tests or OddsPath calculations are explicitly reported.",
              "judgment": "No",
              "reasoning": "The abstract lacks statistical validation or quantitative measures of pathogenicity.",
              "next_step_or_outcome": "Proceed to Sub-step 4b"
            },
            {
              "step_name": "Sub-step 4b: No OddsPath Calculation",
              "extracted_paper_info": "Three pathogenic variants (A30P, E46K, A53T) were compared to wildtype. No additional control variants are described.",
              "judgment": "10 or less",
              "reasoning": "Only three pathogenic variants are analyzed, totaling fewer than 10 controls.",
              "next_step_or_outcome": "Max PS3_supporting"
            }
          ]
        }
      ],
      "evidence_strength": "PS3_supporting"
    }
  ]
}